Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lineage Commitment01:21

Lineage Commitment

3.0K
Commitment is the  process whereby stem cells:
3.0K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.0K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
Hematopoiesis01:21

Hematopoiesis

5.1K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.1K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

304
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
304

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dissecting cancer in a non-mammalian model: genomic insights from lemon frost geckos.

BMC biology·2026
Same author

Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities.

Bone marrow transplantation·2026
Same author

Timing is everything: outcomes of allogeneic HSCT in adults with inborn errors of immunity.

Bone marrow transplantation·2026
Same author

Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMT.

Bone marrow transplantation·2026
Same author

Dipeptidyl peptidase 3 sets the threshold for immune activation and survival during experimental bacterial infection.

Nature communications·2026

Related Experiment Video

Updated: Jun 9, 2025

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

3.5K

Long-term lineage commitment in haematopoietic stem cell gene therapy.

Andrea Calabria1, Giulio Spinozzi2, Daniela Cesana2

  • 1San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy. calabria.andrea@hsr.it.

Nature
|October 23, 2024
PubMed
Summary

Gene therapy using hematopoietic stem cells (HSCs) can restore blood cell function. However, inherited diseases and age impact HSCs, causing them to adapt and favor specific blood cell types.

More Related Videos

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

910
Isolation Method for Long-Term and Short-Term Hematopoietic Stem Cells
06:41

Isolation Method for Long-Term and Short-Term Hematopoietic Stem Cells

Published on: May 19, 2023

1.7K

Related Experiment Videos

Last Updated: Jun 9, 2025

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

3.5K
Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

910
Isolation Method for Long-Term and Short-Term Hematopoietic Stem Cells
06:41

Isolation Method for Long-Term and Short-Term Hematopoietic Stem Cells

Published on: May 19, 2023

1.7K

Area of Science:

  • * Hematology
  • * Gene Therapy
  • * Stem Cell Biology

Background:

  • * Hematopoietic stem cell gene therapy (HSC-GT) offers potential for lifelong correction of genetic blood disorders.
  • * The long-term impact of genetic diseases, cellular stress, and aging on HSC function and blood cell development remains incompletely understood.
  • * Understanding these factors is crucial for optimizing gene therapy outcomes.

Purpose of the Study:

  • * To investigate the long-term hematopoietic reconstitution and lineage specification in patients undergoing lentiviral HSC-GT.
  • * To analyze the influence of underlying genetic diseases, patient age, and disease severity on HSC behavior and clonal output.
  • * To identify adaptive mechanisms of HSCs in response to pathological conditions.

Main Methods:

  • * Analysis of hematopoietic reconstitution in 53 patients treated with lentiviral-HSC-GT for metachromatic leukodystrophy, Wiskott-Aldrich syndrome, and β-thalassemia.
  • * Longitudinal follow-up up to 8 years, utilizing vector integration sites to track clonal identity and expansion.
  • * Assessment of HSC numbers, multi-lineage potential, lineage-specific commitment, and somatic mutation rates.

Main Results:

  • * Long-term hematopoietic reconstitution was sustained by a significant number of active HSCs (770 to 35,000).
  • * 50% of transplanted clones exhibited multi-lineage potential across all studied conditions.
  • * A subset of clones showed disease-specific lineage preference (myeloid for MLD, lymphoid for WAS, erythroid for β-thalassemia), particularly in adult patients.
  • * HSC behavior, including clonogenic activity, lineage output, and mutation rates, was significantly influenced by the underlying disease and patient age.

Conclusions:

  • * Hematopoietic stem cells demonstrate adaptive responses to pathological conditions during gene therapy and reconstitution.
  • * The long-term success of HSC-GT is modulated by the interplay between the inherited disease, patient age, and therapeutic interventions.
  • * Disease-specific lineage commitment observed in HSC clones highlights the complex interactions between genetic defects and stem cell behavior.